As an economic and financial center, Shanghai has outstanding advantages in integrated circuits, biomedicine and new materials. The introduction of this merger and reorganization plan highlights Shanghai's determination to actively develop new quality productive forces and achieve autonomy and control.Analysts said that the plan is expected to benefit Shanghai local stocks from multiple dimensions.From the perspective of institutional attention, Zhongwei Company and Weir Co., Ltd. have more than 30 institutional ratings, while Hengxuan Technology, Lanqi Technology, UIH Medical and Microelectrophysiology -U have more than 20 institutional ratings.
As an economic and financial center, Shanghai has outstanding advantages in integrated circuits, biomedicine and new materials. The introduction of this merger and reorganization plan highlights Shanghai's determination to actively develop new quality productive forces and achieve autonomy and control.According to the key industrial fields mentioned in the action plan, Shanghai's local semiconductor leading enterprises, pharmaceutical leading enterprises and new material leading enterprises are also expected to benefit from the merger and acquisition plan.In the secondary market, the concept stocks of M&A and restructuring rose strongly, and the restructuring index rose nearly 63% since September 24th.
It is worth mentioning that among the stocks with a market value of less than 10 billion yuan, Kaikai Industry, Fudan Fuhua, First Hospital and Xuantai Medicine all belong to the biomedical industry. Among the state-owned shares in Shanghai, Hua Hong Company and Hehui Optoelectronics -U belong to the semiconductor industry.In addition, the market value of Zhongwei Company, Weir Shares and UIH Medical all exceeded 100 billion yuan.